21,000 Beam Therapeutics Inc. $BEAM Shares Bought by Privium Fund Management B.V.

Privium Fund Management B.V. raised its stake in shares of Beam Therapeutics Inc. (NASDAQ:BEAM) by 29.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 91,282 shares of the company’s stock after purchasing an additional 21,000 shares during the quarter. Privium Fund Management B.V. owned 0.09% of Beam Therapeutics worth $2,232,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Alphabet Inc. bought a new position in shares of Beam Therapeutics during the 2nd quarter worth approximately $11,037,000. VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Beam Therapeutics in the 2nd quarter valued at $1,309,000. Canal Insurance CO bought a new stake in Beam Therapeutics in the first quarter valued at $953,000. Legal & General Group Plc bought a new stake in Beam Therapeutics in the second quarter valued at $2,717,000. Finally, Jupiter Topco LLC bought a new stake in Beam Therapeutics in the second quarter valued at $3,259,000. 99.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Beam Therapeutics news, CEO John Evans sold 25,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $23.57, for a total transaction of $589,250.00. Following the sale, the chief executive officer owned 1,047,205 shares of the company’s stock, valued at $24,682,621.85. This represents a 2.33% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.80% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

BEAM has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating on shares of Beam Therapeutics in a research note on Tuesday, October 27th. Canaccord Genuity Group dropped their target price on shares of Beam Therapeutics from $79.00 to $78.00 and set a “buy” rating for the company in a research report on Wednesday. William Blair upgraded shares of Beam Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. Wedbush lifted their price target on shares of Beam Therapeutics from $28.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Guggenheim reduced their price target on shares of Beam Therapeutics from $55.00 to $51.00 and set a “buy” rating on the stock in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $47.36.

Beam Therapeutics Price Performance

BEAM traded up $0.54 during trading on Friday, hitting $26.41. The company’s stock had a trading volume of 1,984,858 shares, compared to its average volume of 1,916,265. The company has a quick ratio of 14.57, a current ratio of 14.57 and a debt-to-equity ratio of 0.09. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of -25.39 and a beta of 2.23. The firm’s 50 day moving average price is $25.58 and its two-hundred day moving average price is $28.03. Beam Therapeutics Inc. has a 12 month low of $20.23 and a 12 month high of $38.26.

Beam Therapeutics (NASDAQ:BEAM) last announced its earnings results on Tuesday, November 3rd. The company reported ($1.28) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.11). Beam Therapeutics had a negative return on equity of 30.71% and a negative net margin of 54.75%. The business had revenue of $0.31 million for the quarter, compared to the consensus estimate of $8.75 million. During the same quarter in the previous year, the company posted ($1.10) EPS. Beam Therapeutics’s revenue for the quarter was down 96.8% on a year-over-year basis. Sell-side analysts forecast that Beam Therapeutics Inc. will post -4.65 earnings per share for the current fiscal year.

Beam Therapeutics Profile

Beam Therapeutics Inc is a biotechnology company developing precision genetic medicines for patients with serious diseases. The company’s platform uses base editing, a form of gene editing designed to make targeted changes to individual DNA letters without creating double-strand breaks. Beam is also advancing related editing technologies and delivery systems intended to improve the precision and effectiveness of genetic treatments.

Beam’s pipeline includes investigational programs for diseases such as sickle cell disease, beta thalassemia, alpha-1 antitrypsin deficiency and glycogen storage disease type Ia.